Midday movers: Nvidia, Apple and GameStop rise; Tesla, DraftKings fall
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/18/2026
- Wall St ends lower for the day and week as chip selloff broadens
- Netflix earnings forecast disappoints Wall Street, shares tumble
- HSBC upgrades Apple to Buy, sees "strong cycle ahead"
- Kimi K3 AI breakthrough: What Wall Street analysts say about China’s OpenAI threat
- Why the Fed may still need to hike rates
- Assassin's Creed Black Flag Resynced sells 3M copies in a week
- Magnitude 7.4 earthquake strikes coast of Chiapas, Mexico; Tsunami waves are possible
- Magnitude 7.4 earthquake strikes Puerto Madero, Mexico, USGS says
- Medifast launches Trilivy, replacing its Optavia brand
- Adobe has received a takeover approach by a Big Tech company - Betaville
Insmed (INSM) PT Raised to $67 at Stifel
May 30, 2024 4:35 PM EDTStifel analyst Stephen D. Willey raised the price target on Insmed (NASDAQ: INSM) to $67.00 (from $39.00) while maintaining a Buy rating.
The analyst comments "We believe topline P3 ASPEN results will establish brensocatib as the first-approved, standardof-care therapy in NCFBE and meaningfully improve investor... More
Citi Reiterates Buy Rating on NVIDIA (NVDA)
May 29, 2024 9:19 AM EDTCiti analyst Atif Malik reiterated a Buy rating and $1,260.00 price target on NVIDIA (NASDAQ: NVDA).
The analyst comments "Mercury Research released 1Q24 graphics data yesterday. While the data is backward-looking, on a Q/Q basis, NVDA GPU revenue share was down 40bps (93.5%)... More
Apple: Evercore weighs on the impact EU DMA Implementation has on App Store
May 29, 2024 7:00 AM EDTEvercore ISI recently evaluated the effects of Apple's (NASDAQ: AAPL) compliance with the European Union's Digital Markets Act (DMA) on App Store sales.
Despite significant regulatory changes implemented in early March, their analysis indicates minimal impact on revenue from the EU App Store, which accounts for approximately $1.2... More
UBS Reiterates Buy Rating on Flutter Entertainment Plc. (FLTR:LN) (FLUT)
May 29, 2024 6:10 AM EDTUBS analyst Louise Wiseur reiterated a Buy rating and GBP217.00 price target on Flutter Entertainment Plc. (FLTR:LN) (NYSE: FLUT).
The analyst comments "In a note following our assumption of coverage, we explicitly modelled out taxation in the US on a... More
CAVA Group Inc (CAVA) PT Raised to $77 at JPMorgan
May 29, 2024 5:42 AM EDTJPMorgan analyst John Ivankoe raised the price target on CAVA Group Inc (NYSE: CAVA) to $77.00 (from $64.00) while maintaining a Overweight rating.
The analyst comments "CAVA results - and resulting stock price - are demonstrating a visible expansion from multi-regional success to eventual national scale. We... More
Insmed (INSM) PT Raised to $58 at UBS
May 29, 2024 5:37 AM EDTUBS analyst Trung Huynh raised the price target on Insmed (NASDAQ: INSM) to $58.00 (from $46.00) while maintaining a Buy rating.
The analyst comments "Management believes from now through the regulatory review process, the path is noncontroversial given the strength of data presented... More
Insmed (INSM) PT Raised to $68 at Truist Securities
May 29, 2024 5:30 AM EDTTruist Securities analyst Nicole Germino raised the price target on Insmed (NASDAQ: INSM) to $68.00 (from $48.00) while maintaining a Buy rating.
The analyst comments "With greater confidence into brensocatib potential approval following positive ASPEN results today and supported by our KOL call last... More
Insmed (INSM) PT Raised to $54 at Wolfe Research
May 29, 2024 5:25 AM EDTWolfe Research analyst Andy Chen raised the price target on Insmed (NASDAQ: INSM) to $54.00 (from $42.00) while maintaining a Outperform rating.
The analyst comments "How to think about stock valuation, even assuming a capital raise? The previous stock in the mid-$20s implied POS... More
CAVA Group Inc (CAVA) PT Raised to $85 at Morgan Stanley
May 29, 2024 5:24 AM EDTMorgan Stanley analyst Brian Harbour raised the price target on CAVA Group Inc (NYSE: CAVA) to $85.00 (from $68.00) while maintaining a Overweight rating.
The analyst comments "Our view on the stock at this point: We remain OW the shares here, and after having doubled YTD, risk-reward skew isn't as compelling as it was and we've had to... More
Evercore ISI Reiterates Outperform Rating on Apple (AAPL)
May 29, 2024 5:16 AM EDTEvercore ISI analyst Amit Daryanani reiterated an Outperform rating and $220.00 price target on Apple (NASDAQ: AAPL).
The analyst comments "The Chinese smartphone market was up ~29% y/y in April, a notable improvement vs the -5.5% reported in March. CAICT data suggests MNC shipments (read: Apple) were up ~52% y/y (total 3.5M units) an acceleration vs the +12% reported in March. There is likely an element of refilling the... More
Insmed (INSM) PT Raised to $62 at BofA Securities
May 29, 2024 5:08 AM EDTBofA Securities analyst Jason Zemansky raised the price target on Insmed (NASDAQ: INSM) to $62.00 (from $40.00) while maintaining a Buy rating.
The analyst comments "This mornings positive readout for novel DPP-1 inhibitor brenso (see report: our initial takes on the data) represents a... More
Celsius Holdings (CELH) PT Raised to $84 at BofA Securities
May 29, 2024 5:06 AM EDTBofA Securities analyst Jonathan Keypour raised the price target on Celsius Holdings (NASDAQ: CELH) to $84.00 (from $80.00) while maintaining a Neutral rating.
The analyst comments "After speaking to management today following the sharp stock price reaction to Nielsen data through May 18th, we heard... More
CAVA Group Inc (CAVA) PT Raised to $87 at Citi
May 29, 2024 4:59 AM EDTCiti analyst Jon Tower raised the price target on CAVA Group Inc (NYSE: CAVA) to $87.00 (from $81.00) while maintaining a Neutral rating.
The analyst comments "Investor expectations were high heading into the print (shares +92% YTD) and CAVA delivered another strong quarter/outlook where... More
UBS Reiterates Buy Rating on DraftKings Inc. (DKNG)
May 28, 2024 4:03 PM EDTUBS analyst Robin Farley reiterated a Buy rating and $60.00 price target on DraftKings Inc. (NASDAQ: DKNG).
The analyst comments "ILs State Senate passed a progressive tax on online sports betting GGR, and it could to pass the IL House by the end of extended session this week. The tax rate starts at 20% tax on GGR up to $30m; 25% for $30m-$50m; 30% for $50m-$100m; 35% for $100m-$200m and 40% on $200m+. This represents an increase from 15% current tax rate when the state first legalized in June 2021 and compares to the proposed 35% increase from... More
Insmed (INSM) PT Raised to $60 at Morgan Stanley
May 28, 2024 2:37 PM EDTMorgan Stanley analyst Jeffrey Hung raised the price target on Insmed (NASDAQ: INSM) to $60.00 (from $43.00) while maintaining a Overweight rating.
The analyst comments "With clear positive results from the ASPEN topline data, questions on the conference call focused more on the potential commercial... More
Citi Defending DraftKings Inc. (DKNG)
May 28, 2024 1:54 PM EDTCiti analyst Steven Sheeckutz reiterated a Buy rating and $57.00 price target on DraftKings Inc. (NASDAQ: DKNG).
The analyst comments "Over the weekend, the Illinois Senate approved a state budget that, if approved by the House, would push online sports book (OSB)... More
Goldman Sachs Reiterates Buy Rating on Insmed (INSM)
May 28, 2024 1:27 PM EDTGoldman Sachs analyst Andrea Tan reiterated a Buy rating and $74.00 price target on Insmed (NASDAQ: INSM).
The analyst comments "INSM announced positive topline ASPEN data in patients with non-CF bronchiectasis where brensocatib treatment resulted in statistically significant and clinically meaningful reductions in the frequency of pulmonary exacerbations (21.1%/19.4% for 10mg/25mg, respectively) along with benefit on various... More
JPMorgan Reiterates Overweight Rating on DraftKings Inc. (DKNG)
May 28, 2024 11:28 AM EDTJPMorgan analyst Joseph Greff reiterated an Overweight rating and $56.00 price target on DraftKings Inc. (NASDAQ: DKNG).
The analyst comments "DKNG shares are down ~11% this morning following news over the holiday weekend that Illinois Senate passed a bill to implement a new progressive tax regime for sports betting adjusted gross revenue (essentially gross gaming revenue, with some minor adjustments to exclude voided wagers and other state accounting nuances). Next step for the bill is to go through re-approval by the House (previous version passed by the house did not include a progressive... More
JPMorgan Reiterates Overweight Rating on Apple (AAPL)
May 28, 2024 11:25 AM EDTJPMorgan analyst Samik Chatterjee reiterated an Overweight rating and $225.00 price target on Apple (NASDAQ: AAPL)
The analyst comments "Post F2Q24 earnings results in which Greater China saw better than feared revenue, the latest data for April continues to show an improving trajectory for iPhone shipments in China, even though a... More
JPMorgan Reiterates Overweight Rating on Insmed (INSM)
May 28, 2024 10:45 AM EDTJPMorgan analyst Jessica Fye reiterated an Overweight rating and $36.00 price target on Insmed (NASDAQ: INSM)
The analyst comments "This morning Insmeds ASPEN study hit a home run scenario. Both the 10mg and 25mg doses reached statistical significance with p-values less than 0.01... More
Morgan Stanley Reiterates Overweight Rating on DraftKings Inc. (DKNG)
May 28, 2024 10:26 AM EDTMorgan Stanley analyst Ed Young reiterated an Overweight rating and $51.00 price target on DraftKings Inc. (NASDAQ: DKNG)
The analyst comments "The IL tax hike has been proposed for several months but now appears likely to be approved, raising concerns of other states potentially following suit. DKNG does have levers to help offset headwinds (reduced promo/marketing) but the outcome likely creates an... More
CFRA Reiterates Buy Rating on Apple (AAPL)
May 28, 2024 8:27 AM EDTCFRA analyst Angelo Zino reiterated a Buy rating and $210.00 price target on Apple (NASDAQ: AAPL).
The analyst comments "Workhorse missed 1Q24 revenue forecasts on slow deliveries. Shares out have increased by 61m (as of May 9) since the 315m outstanding at the end of 2023,... More
Stifel Reiterates Buy Rating on Insmed (INSM)
May 28, 2024 7:54 AM EDTStifel analyst Stephen D. Willey reiterated a Buy rating and $35.00 price target on Insmed (NASDAQ: INSM).
The analyst comments "This mornings top-line disclosure of P3 ASPEN data represents, in our opinion, a best-case scenario for INSM shares with top-line data not only supportive of what we (conservatively) believe to represent a $2.5B+ commercial opportunity in NCFBE, but also improving visibility into future label expansion opportunities such as CRSsNP (P2 ongoing) and HS (P2 now likely to initiate). We believe todays disclosure also eliminates all balance sheet and capital structure concerns... More
Evercore ISI Reiterates Outperform Rating on Insmed (INSM)
May 28, 2024 7:36 AM EDTEvercore ISI analyst Liisa Bayko reiterated an Outperform rating and $42.00 price target on Insmed (NASDAQ: INSM).
The analyst comments "Highly anticipated ASPEN data is the best-case scenario for INSM with both doses of brensocatib reaching the primary & multiple secondary endpoints.... More
